专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004091510A2 RECOMBINANT IL-9 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：重组IL-9抗体及其用途
公开(公告)号：WO2004091510A2
公开(公告)日：2004-10-28
申请号：PCT/US2004011172
申请日：2004-04-12
申请人： MEDIMMUNE INC , REED JENNIFER L
发明人： REED JENNIFER L
IPC分类号： A61K39/395 , C07K16/24 , G01N33/53 , A61K
CPC分类号： C07K16/244 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/76 , C07K2317/92 , G01N33/6869
摘要： The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.
摘要翻译：本发明提供免疫特异性结合IL-9多肽的新型抗体和包含所述抗体的组合物。本发明还提供了预防，治疗，治疗和/或改善与IL 9或IL-9受体或其亚基的异常表达和/或活性相关的疾病和病症的方法和组合物，自身免疫性疾病，炎性疾病，增殖性疾病，以及感染，其包括施用一种或多种免疫特异性结合IL-9多肽的抗体。本发明还包括用于诊断，监测和预测这些疾病的方法和组合物。本发明还涉及包含免疫特异性结合IL-9多肽的抗体的制品和试剂盒。

2. 发明申请

WO2004091375A2 EPHA2 AND HYPERPROLIFERATIVE CELL DISORDERS 审中-公开
标题翻译： EPHA2和高增殖性细胞病变
公开(公告)号：WO2004091375A2
公开(公告)日：2004-10-28
申请号：PCT/US2004/011482
申请日：2004-04-12
申请人： MEDIMMUNE, INC. , KIENER, Peter, A. , KINCH, Michael, S. , LANGERMANN, Solomon , REED, Jennifer, L.
发明人： KIENER, Peter, A. , KINCH, Michael, S. , LANGERMANN, Solomon , REED, Jennifer, L.
IPC分类号： A61B
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/32
摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation. in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype ( e.g ., a pathology-causing epithelial cell phenotype or a pathology-causing endothelial cell phenotype). In another embodiment, the methods of the invention comprise the administration of an effective amount. of one or more EphA2 agonistic agents that are EphA2 antibodies that bind to EphA2 with a very low K off rate. In prefer-red embodiments, agents of the invention are inonoclonal antibodies. The invention also provides pharmaceutical compositions comprising one or more EphA2 agonistic agents of the invention either alone or in combination with one or more other agents useful in therapy for non-neoplastic hyperproliferative cell or excessive cell accumulation disorders.
摘要翻译：本发明涉及设计用于治疗，管理或预防非肿瘤性过度增殖性细胞或过度细胞累积障碍，特别是涉及上皮细胞或内皮细胞过度增殖的方法和组合物。在一个实施方案中，本发明的方法包括施用有效量的一种或多种结合EphA2并增加EphA2细胞质尾磷酸化和/或增加EphA2自磷酸化的EphA2激动剂。在EphA2被激活的细胞中。在另一个实施方案中，本发明的方法包括施用有效量的一种或多种EphA2激动剂，其结合EphA2并降低EphA2活性（除了自磷酸化）。在另一个实施方案中，本发明的方法包括施用有效量的一种或多种结合EphA2的EphA2激动剂并减少病理学引起的细胞表型（例如，导致病理的上皮细胞表型或致病性病因的内皮细胞表型）。在另一个实施方案中，本发明的方法包括施用有效量。的一种或多种EphA2激动剂，其是以非常低的Koff率与EphA2结合的EphA2抗体。在优选的实施方案中，本发明的试剂是异源抗体。本发明还提供包含本发明的一种或多种EphA2激动剂的药物组合物，其单独或与一种或多种其它可用于治疗非肿瘤性过度增殖性细胞或过度细胞累积障碍的其它药物组合。

3. 发明申请

WO2004091519A2 METHODS OF PREVENTING OR TREATING RESPIRATORY CONDITIONS 审中-公开
标题翻译：预防或治疗呼吸道条件的方法
公开(公告)号：WO2004091519A2
公开(公告)日：2004-10-28
申请号：PCT/US2004/011329
申请日：2004-04-12
申请人： MEDIMMUNE, INC. , REED, Jennifer, L.
发明人： REED, Jennifer, L.
IPC分类号： A61K
CPC分类号： A61K45/06 , A61K31/381 , A61K31/4045 , A61K31/47 , A61K31/473 , A61K39/395 , A61K2039/505 , C07K16/244 , C07K2317/76 , A61K2300/00
摘要： The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managinge, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present invention encompasses combination therapies, pharmaceutical compositions, articles of manufacture, and kits.
摘要翻译：本发明提供预防性治疗方案，其旨在预防，治疗，或改善呼吸状况或其一种或多种症状。特别地，本发明提供了预防，治疗或改善由环境因素或呼吸道感染引起的呼吸状况或一种或多种症状的方法。本发明包括组合疗法，药物组合物，制品和试剂盒。

4. 发明申请

WO2004091519A3 METHODS OF PREVENTING OR TREATING RESPIRATORY CONDITIONS 审中-公开
标题翻译：预防或治疗呼吸道条件的方法
公开(公告)号：WO2004091519A3
公开(公告)日：2007-08-02
申请号：PCT/US2004011329
申请日：2004-04-12
申请人： MEDIMMUNE INC , REED JENNIFER L
发明人： REED JENNIFER L
IPC分类号： A61K39/395 , A61K20060101 , A61K31/47 , A61K39/42 , A61K45/00 , A61K45/06 , C07K16/00 , C07K16/24
CPC分类号： A61K45/06 , A61K31/381 , A61K31/4045 , A61K31/47 , A61K31/473 , A61K39/395 , A61K2039/505 , C07K16/244 , C07K2317/76 , A61K2300/00
摘要： The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managinge, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present invention encompasses combination therapies, pharmaceutical compositions, articles of manufacture, and kits.
摘要翻译：本发明提供预防性治疗方案，其旨在预防，治疗，或改善呼吸状况或其一种或多种症状。特别地，本发明提供了预防，治疗或改善由环境因素或呼吸道感染引起的呼吸状况或一种或多种症状的方法。本发明包括组合疗法，药物组合物，制品和试剂盒。

5. 发明申请

WO2004091510A3 RECOMBINANT IL-9 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2004091510A3
公开(公告)日：2004-10-28
申请号：PCT/US2004/011172
申请日：2004-04-12
申请人： MEDIMMUNE, INC. , REED, Jennifer, L. , WU, Herren , TANG, Ying , DAVIES, Julian , WATKINS, Jeffry, D.
发明人： REED, Jennifer, L. , WU, Herren , TANG, Ying , DAVIES, Julian , WATKINS, Jeffry, D.
IPC分类号： A61K39/395
摘要： The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

6. 发明申请

WO2004091375A3 EPHA2 AND NON-NEOPLASTIC HYPERPROLIFERATIVE CELL DISORDERS 审中-公开
标题翻译： EPHA2和非神经性高增殖性细胞病变
公开(公告)号：WO2004091375A3
公开(公告)日：2005-07-14
申请号：PCT/US2004011482
申请日：2004-04-12
申请人： MEDIMMUNE INC , KIENER PETER A , KINCH MICHAEL S , LANGERMANN SOLOMON , REED JENNIFER L
发明人： KIENER PETER A , KINCH MICHAEL S , LANGERMANN SOLOMON , REED JENNIFER L
IPC分类号： A61B20060101 , A61K39/00 , A61K39/395 , A61K49/00 , C07K16/28 , C07K16/32
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/32
摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation. in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype (e.g., a pathology-causing epithelial cell phenotype or a pathology-causing endothelial cell phenotype). In another embodiment, the methods of the invention comprise the administration of an effective amount. of one or more EphA2 agonistic agents that are EphA2 antibodies that bind to EphA2 with a very low Koff rate. In prefer-red embodiments, agents of the invention are inonoclonal antibodies. The invention also provides pharmaceutical compositions comprising one or more EphA2 agonistic agents of the invention either alone or in combination with one or more other agents useful in therapy for non-neoplastic hyperproliferative cell or excessive cell accumulation disorders.
摘要翻译：本发明涉及设计用于治疗，管理或预防非肿瘤性过度增殖性细胞或过度细胞累积障碍，特别是涉及上皮细胞或内皮细胞过度增殖的方法和组合物。在一个实施方案中，本发明的方法包括施用有效量的一种或多种结合EphA2并增加EphA2细胞质尾磷酸化和/或增加EphA2自磷酸化的EphA2激动剂。在EphA2被激活的细胞中。在另一个实施方案中，本发明的方法包括施用有效量的一种或多种EphA2激动剂，其结合EphA2并降低EphA2活性（除了自磷酸化）。在另一个实施方案中，本发明的方法包括施用有效量的一种或多种结合EphA2的EphA2激动剂并减少病理学引起的细胞表型（例如，导致病理的上皮细胞表型或致病性病因的内皮细胞表型）。在另一个实施方案中，本发明的方法包括施用有效量。的一种或多种EphA2激动剂，其是以非常低的Koff率与EphA2结合的EphA2抗体。在优选的实施方案中，本发明的试剂是异源抗体。本发明还提供包含本发明的一种或多种EphA2激动剂的药物组合物，其单独或与一种或多种其它可用于治疗非肿瘤性过度增殖性细胞或过度细胞累积障碍的其它药物组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式